Goldman Sachs analyst Andrea Tan raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $51 from $45 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Tarsus Pharmaceuticals: Strong Market Performance and Growth Potential Justify Buy Rating
- Strong Market Position and Growth Potential Drive Buy Rating for Tarsus Pharmaceuticals
- Tarsus Pharmaceuticals Reports Strong Q3 2025 Growth
- Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Justify Buy Rating